Acutaas Chemicals Ltd.
ACUTAASNSEHealthcarePharmaceuticals & DrugsSmall Cap
₹3,246.2
▲ 3.5%
loading…
71
Composite
The company is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals.
Q-DITS fundamental score
71Composite
Growth
99
Profitability
62
Valuation
0
Quality
77
Solvency
70
Earnings
96
Key metrics
MCap
₹26.6K Cr
TTM PE
74.5x
Industry PE
38.2x
TTM EPS
₹43.51
Book Value
₹201.97
Face Value
₹5
Div Yield
0.08%
PEG
1.2x
PB
15.3x
ROE
16.2%
ROCE
20.1%
EBITDA mgn
24.7%
D/E
0.01
Int. Cover
35.8x
Curr. Ratio
3.91x
EPS
₹9.69
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 33% | 29.5% | 31.5% | — |
| EBITDA | 107% | 57.7% | 43.1% | — |
| Net Profit | 124.5% | 62.3% | 45.8% | — |
Score snapshot
Piotroski
8/9
Altman Z
2.13
Quality
76.9
Growth
99.4
Valuation
0
Earn. Qual
95.5
PEAD
+2
SURGE
+1
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap a row to expand the full chart
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 154 | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | |
| ›EBITDACr | 21 | 23 | 33 | 42 | 44 | 82 | 108 | 127 | 104 | 249 | |
| ›EBITDA margin | 13.7% | 14.6% | 17.8% | 17.8% | 18.3% | 23.9% | 20.8% | 20.6% | 19% | 24.7% | |
| ›Net profitCr | 13 | 12 | 19 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | |
| ›PAT margin | 8.2% | 7.5% | 9.8% | 9.8% | 11.5% | 15.9% | 13.8% | 13.5% | 6.8% | 15.9% | |
| ›EPS₹ | ₹2.01 | ₹1.91 | ₹2.95 | ₹3.7 | ₹4.36 | ₹2.86 | ₹9.87 | ₹11.43 | ₹5.8 | ₹9.69 | |
| ›Revenue growth | 0% | 4.3% | 17.4% | 26.7% | 0.5% | 42.1% | 52.7% | 18.6% | 16.3% | 40.3% | |
| ›PAT growth | 0% | -4.8% | 53.5% | 26% | 17.9% | 96.6% | 33.2% | 15.8% | -41.5% | 229.3% | |
| ›ROE | 46.4% | 36.4% | 39% | 34.6% | 29.8% | 40.5% | 21.1% | 14.9% | 7.7% | 16.2% | |
| ›ROCE | 35.5% | 35.9% | 38.2% | 34.3% | 27.1% | 33.4% | 23.9% | 20.4% | 11.8% | 20.1% | |
| ›ROA | 13.9% | 12% | 14% | 12.6% | 12.3% | 16.7% | 13.4% | 11.7% | 5.2% | 12.1% | |
| ›P/E | 0x | 0x | 0x | 0x | 0x | 0x | 50.6x | 19.4x | 47.2x | 63x | |
| ›P/B | 0x | 0x | 0x | 0x | 0x | 0x | 7x | 5.5x | 6x | 15.3x | |
| ›D/E | 1.1 | 0.7 | 0.8 | 0.7 | 0.6 | 0.9 | 0 | 0 | 0.3 | 0 | |
| ›Current ratio | 1.4x | 1.2x | 1.3x | 1.2x | 1.3x | 1.3x | 3.3x | 2.8x | 1.7x | 3.9x | |
| ›Interest cover | 7.9x | 6.7x | 9.8x | 8.4x | 7.2x | 13.8x | 15.3x | 47.5x | 14.8x | 35.8x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | |
| ›Rev growth YoY | 9.2% | 20.7% | 14.9% | 43.2% | 65.2% | 37.1% | 17.3% | 24.1% | 43% | 40.3% | |
| ›EBITDACr | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | |
| ›EBITDA margin | 15.9% | 19.2% | 16.7% | 19.8% | 25% | 27.5% | 24.6% | 31.1% | 38.3% | 42.4% | |
| ›Net profitCr | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | |
| ›PAT growth YoY | -20.1% | -5.6% | -33.9% | 320.7% | 155.2% | 144.2% | 199.6% | 91.3% | 133.7% | 114.1% | |
| ›EPS₹ | ₹4.54 | ₹6.82 | ₹3.41 | ₹9.12 | ₹10.98 | ₹7.63 | ₹5.41 | ₹8.82 | ₹13.19 | ₹16.09 |
Balance sheet — last 10 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 39 | 58 | 82 | 112 | 167 | 522 | 594 | 674 | 1,310 | 1,654 | |
| ›ReservesCr | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 635 | 1,269 | 1,613 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 3 | 5 | 5 | 8 | 4 | 22 | 21 | 50 | 57 | 0 | |
| ›Total assetsCr | 54 | 90 | 105 | 134 | 244 | 523 | 595 | 798 | 1,327 | 1,984 | |
| ›Current assetsCr | 66 | 87 | 124 | 121 | 216 | 430 | 457 | 493 | 792 | 881 | |
| ›Current liabilitiesCr | 55 | 65 | 106 | 95 | 166 | 129 | 163 | 285 | 202 | 231 | |
| ›Trade payablesCr | 38 | 48 | 68 | 51 | 85 | 118 | 142 | 135 | 156 | 154 | |
| ›Gross blockCr | 35 | 41 | 91 | 98 | 203 | 231 | 298 | 482 | 652 | 583 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 29 | 8 | 15 | 27 | 28 | -12 | 66 | 125 | 118 | 292 | |
| ›Investing CF (CFI)Cr | -19 | -25 | -21 | -24 | -101 | -121 | -33 | -365 | -224 | -266 | |
| ›Financing CF (CFF)Cr | -7 | 15 | 6 | 0 | 72 | 140 | -12 | 239 | 261 | 4 | |
| ›Net cash changeCr | 3 | -2 | -0 | 3 | -1 | 8 | 20 | -1 | 156 | 30 | |
| ›Closing cashCr | 3 | 1 | 0 | 4 | 3 | 10 | 31 | 30 | 185 | 216 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
71
Quality (25%)76.9
Growth (25%)99.4
Valuation (20%)0
Piotroski (15%)89
Earnings Quality (10%)95.5
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
8/9
✓ROA positiveROA 12.13%
✓CFO positiveCFO ₹292.17 Cr
✓ROA improving5.23% → 12.13%
✓CFO > PAT (low accruals)CFO 292.17 vs PAT 160.42
✓Leverage decreasedD/E 0.32 → 0.01
✓Liquidity improvedCR 1.73 → 3.91
✓No share dilutionEPS 5.8 → 9.69
✓Margin improvedEBITDA mgn 18.95% → 24.73%
✗Asset turnover upAsset TO 0.77 → 0.76
Altman Z-Scoregrey
2.13
X1
0.328
X2
0.813
X3
0.112
X4
0.833
X5
0.508
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
76.9/100
ROE
16.2%
ROCE
20.1%
Margin
15.9%
Debt
0
Int. cover
35.8x
Growth
99.4/100
Revenue 3Y
29.5%
Profit 3Y
62.3%
EPS
67.2%
Valuation
0/100
PE
63x
PB
15.3x
EV/EBITDA
39.2x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
95.5/100
CFO₹292 Cr
PAT₹160 Cr
Accrual ratio-0.066
CFO/PAT1.82x
PEAD · SURGE
+2 / +1
Revenue SUE0.58
EPS SUE2.82
Latest quarter2026-03
Rev growth YoY40.3%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |